Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EDIT-401

Other · developed by Editas Medicine

Phase 1/2 Most advanced trial
EDIT Developer
1 Registered trials

What is EDIT-401?

EDIT-401 is a drug studied in heterozygous familial hypercholesterolemia (HeFH), a condition marked by high LDL cholesterol.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Editas Medicine, Inc. (EDIT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07894887 Phase 1/2 Heterozygous Familial Hypercholesterolemia (HeFH) Not yet recruiting EDIT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heterozygous Familial Hypercholesterolemia (HeFH)

More from Editas Medicine

Follow EDIT, the company behind EDIT-401

See EDIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EDIT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.